Drug Details
| General Information of the Drug (ID: DR3388) | ||||
|---|---|---|---|---|
| Name |
Daratumumab
|
|||
| Molecular Type |
Antibody
|
|||
| Disease | Multiple myeloma [ICD-11: 2A83] | Approved | [1] | |
| ADMET Property |
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 4017 mgday/L
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 592 mg/L
Clearance
The clearance of drug is 171.4 +/- 95.3 mL/day
Half-life
The concentration or amount of drug in body reduced by one-half in 18 +/- 9 days
Metabolism
The drug is metabolized via proteolytic enzymes
Vd
The volume of distribution (Vd) of drug is 4.7 +/- 1.3 L
Click to Show/Hide
|
|||
| TTD Drug ID | ||||
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Tretinoin | Homo sapiens | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | NOTCH1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | MV4-11 | CVCL_0064 | Childhood acute monocytic leukemia | Homo sapiens | ||
| OCI-AML-3 | CVCL_1844 | Adult acute myeloid leukemia | Homo sapiens | |||
| MOLM-13 | CVCL_2119 | Adult acute myeloid leukemia | Homo sapiens | |||
| U-937 | CVCL_0007 | Adult acute monocytic leukemia | Homo sapiens | |||
| In-vivo Model | For the leukemic model, 3.0 * 105 spleen cells from MV4-11-engrafted mice were injected intravenously into 75 NSG mice. | |||||
| Experimental
Result(s) |
The combination of ATRA plus DARA induced Fc-dependent conjugate formation and cytotoxicity among AML blasts in vitro. Combination treatment also led to reduction in tumor volume and resulted in increased overall survival in murine engraftment models of AML. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Cyclic ADP-ribose hydrolase 1 (CD38) | Molecule Info | [3] | |
| KEGG Pathway | Nicotinate and nicotinamide metabolism | Click to Show/Hide | ||
| 2 | Metabolic pathways | |||
| 3 | Calcium signaling pathway | |||
| 4 | Hematopoietic cell lineage | |||
| 5 | Oxytocin signaling pathway | |||
| 6 | Salivary secretion | |||
| 7 | Pancreatic secretion | |||
| 8 | Epstein-Barr virus infection | |||
| NetPath Pathway | Leptin Signaling Pathway | Click to Show/Hide | ||
| 2 | TCR Signaling Pathway | |||
| Panther Pathway | CCKR signaling map ST | Click to Show/Hide | ||
| WikiPathways | Oxytocin signaling | Click to Show/Hide | ||
